Zopiclone and Eszopiclone: Similar Names, Different Regulatory and Product Contexts
Zopiclone & Eszopiclone: Patient Safety, Regulatory Differences & Clinical Profile
A clinically verified guide to cyclopyrrolone Z-drugs (Zopisign®, Lunesta®), enantiomer pharmacology, complex sleep behavior warnings, and safe insomnia management.
SLEEP HEALTH GUIDE
CLINICAL SUMMARY
Zopiclone (brand name Zopisign®, Imovane®) and Eszopiclone (brand name Lunesta®) belong to the cyclopyrrolone family of non-benzodiazepine GABA-A receptor modulators (“Z-drugs”). Zopiclone is a 50:50 racemic mixture of two stereoisomers ((S)- and (R)-enantiomers), while eszopiclone consists exclusively of the pharmacologically active (S)-enantiomer. Both agents significantly reduce sleep latency and nocturnal awakenings without substantially altering slow-wave sleep architecture. However, both carry a strict FDA Boxed Warning for Complex Sleep Behaviors (sleepwalking, sleep-driving, sleep-eating), must be avoided with alcohol or CNS depressants, and require conservative dosing to avoid next-morning psychomotor impairment and bitter metallic dysgeusia.
01. Quick medicine facts
A concise, source-verified clinical summary table based on official FDA Prescribing Information and National Library of Medicine documentation:
| INFORMATION | ZOPICLONE | ESZOPICLONE |
|---|---|---|
| Chemical Identity | Racemic mixture: (RS)-zopiclone (50% S, 50% R) | Pure single active stereoisomer: (S)-enantiomer |
| Primary Brand Names | Zopisign®, Imovane®, Datolan® | Lunesta® |
| Pharmacological Class | Cyclopyrrolone Non-Benzodiazepine Hypnotic (GABA-A Positive Allosteric Modulator) | |
| Prescription Schedule | Prescription Only (Rx); DEA Controlled Substance (Schedule IV) | |
| Elimination Half-Life | ~5 hours (parent racemic drug) | ~6 hours (up to 9 hours in elderly patients) |
| US FDA Regulatory Status | Widely approved in UK, EU, Canada; not marketed in US | FDA-approved in the United States since 2004 |
| FDA Boxed Warning | Complex Sleep Behaviors (sleepwalking, sleep-driving, sleep-eating resulting in serious injuries or death) | |
02. What are zopiclone and eszopiclone?
Zopiclone and eszopiclone represent the third major category of non-benzodiazepine sedative-hypnotics, chemically distinct from the imidazopyridines (such as zolpidem / Ambien®) and the pyrazolopyrimidines (zaleplon / Sonata®). They belong to the cyclopyrrolone chemical family.
When original zopiclone was synthesized, it contained two mirror-image molecules in equal parts: the (S)-isomer and the (R)-isomer. Receptor binding assays demonstrated that virtually all clinical sedative and hypnotic efficacy resides entirely in the (S)-enantiomer; the (R)-enantiomer is inactive at GABA-A receptors. In 2004, the isolated (S)-isomer was brought to the U.S. market under the generic name eszopiclone (Lunesta®), allowing targeted therapeutic sleep induction at approximately half the milligram dose of racemic zopiclone.
03. Uses and approved indications
Both cyclopyrrolone hypnotics are prescribed for transient and chronic sleep disorders:
| INDICATION CATEGORY | CLINICAL OBJECTIVE & EFFICACY PROFILE |
|---|---|
| Sleep-Onset Insomnia | Dramatically shortens sleep latency (time required to fall asleep), typically facilitating sleep within 15 to 30 minutes of administration. |
| Sleep-Maintenance Insomnia | Because of their intermediate 5- to 6-hour half-life, both agents significantly reduce nocturnal awakenings and increase total sleep duration compared to ultrashort-acting agents. |
| Transient Insomnia (Shift Work / Travel) | Short-term management of situational acute insomnia triggered by schedule disruptions or situational distress. |
04. How do cyclopyrrolones work?
Patient-Centered Biological Explanation
When you prepare for sleep, specialized sleep centers in your hypothalamus release GABA, the brain’s master calming messenger. GABA attaches to inhibitory receptors on wake-promoting nerve cells, quieting brain chatter and allowing you to drift into sleep. When insomnia disrupts this natural process, wakefulness centers stay hyperactive. Zopiclone and eszopiclone bind with precision to the GABA receptor complex, holding the gate open to let negative chloride ions flood the nerve cells. This selectively shuts down the brain’s internal wake engine, triggering natural sleepiness without disrupting deep restorative sleep cycles.
Advanced Neuropharmacology & Subunit Binding
At the molecular level, cyclopyrrolones operate as positive allosteric modulators (PAMs) at pentameric GABA-A receptor complexes:
- Binding Pocket: They bind to a specialized pocket distinct from classical benzodiazepines, located at the α1, α2, and α3 subunit interfaces with the γ2 subunit.
- Sedative vs. Anxiolytic Profiles: Modulation of α1-containing GABA-A receptors mediates rapid sleep induction, while interaction at α2 and α3 subunits contributes to sleep maintenance and mild muscle relaxation.
- Hepatic Metabolism via CYP3A4 & CYP2E1: Zopiclone and eszopiclone are extensively metabolized in the liver via CYP3A4 and CYP2E1 into N-desmethylzopiclone (weakly active) and zopiclone N-oxide (inactive).
05. Available forms and strengths
Dosage forms reflect the chemical distinction between racemic zopiclone and active eszopiclone:
| MEDICATION | AVAILABLE STRENGTHS | RECOMMENDED CLINICAL DOSING ROLE |
|---|---|---|
| Zopiclone Tablets (Zopisign®) | 3.75 mg, 7.5 mg, 10 mg film-coated tablets | 3.75 mg for geriatric/debilitated patients; 7.5 mg standard adult dose; 10 mg maximum clinical threshold. |
| Eszopiclone Tablets (Lunesta®) | 1 mg, 2 mg, 3 mg film-coated round tablets | 1 mg initial starting dose (to minimize next-day impairment); 2 mg or 3 mg if clinically indicated for maintenance. |
PRESCRIPTION REQUIRED (Rx)
Verified Zopiclone Formulations Dispensed by Licensed US Pharmacies
Patients holding a verified clinical prescription can view authentic manufacturer specifications, packaging markers, and dispensing safety protocols for authorized oral formulations:
06. Dosage and administration principles
Clinical Prescribing Mandate: Dosing must always be initiated at the lowest effective dose immediately before getting into bed. Never take a dose in the middle of the night unless at least 7 to 8 hours remain before waking.
- Administration Timing: Take immediately before bedtime on an empty stomach. Taking with or immediately after a high-fat meal delays absorption and impairs hypnotic onset.
- Dedicated 7-to-8 Hour Sleep Window: Do not take either agent unless you have a dedicated full night (at least 7 to 8 hours) to remain in bed before needing to be active or drive.
- Initial Adult Dosing: For eszopiclone, the FDA mandates starting at 1 mg once daily at bedtime. For zopiclone, standard adult initiation is 3.75 mg or 7.5 mg once daily.
- Geriatric Titration: In adults 65 and older, starting dose should not exceed 1 mg eszopiclone or 3.75 mg zopiclone to avert severe morning balance loss and confusion.
07. Common and expected side effects
The side effect profile of cyclopyrrolones is notable for an unusual sensory phenomenon alongside standard sedation:
| SIDE EFFECT | FREQUENCY | CLINICAL PRESENTATION & COPING STRATEGY |
|---|---|---|
| Bitter / Metallic Dysgeusia | Very Common (20%–35%) | A lingering, bitter metallic taste upon awakening, caused by secretion of the drug and metabolites into saliva; rinse mouth with lemon water or brush teeth. |
| Next-Day Somnolence / Hangover | Common (10%–18%) | Lingering morning grogginess; ensure a full 8-hour sleep window and avoid driving if drowsiness persists. |
| Dizziness & Lightheadedness | Common (6%–12%) | Cerebellar GABA modulation; rise slowly from bed to avoid postural instability. |
| Xerostomia (Dry Mouth) | Common (5%–10%) | Reduced salivary secretion; keep water bedside. |
| Anterograde Amnesia | Occasional (2%–5%) | Inability to recall events that occurred after taking the pill; never take the medication before finishing all evening activities. |
08. FDA boxed warnings and complex sleep behaviors
FDA BOXED WARNING: COMPLEX SLEEP BEHAVIORS RESULTING IN SERIOUS INJURY OR DEATH
1. Complex Sleep Behaviors: Complex sleep behaviors, including sleepwalking, sleep-driving, preparing and eating food, making phone calls, and engaging in other activities while not fully awake, have occurred after taking cyclopyrrolone hypnotics. These events can result in severe injuries, accidental burns, falls, motor vehicle collisions, and death.
2. Immediate Discontinuation Mandate: Discontinue zopiclone or eszopiclone immediately if a patient experiences a complex sleep behavior. These behaviors can occur at therapeutic doses, with or without concurrent alcohol use.
3. CNS Depressant Lethality: Co-administration with opioids (such as oxycodone or tramadol) or alcohol can cause fatal respiratory depression and unarousable coma.
Critical Warning Signs Requiring Immediate Emergency Care
- Severe respiratory depression (breathing under 8 breaths per minute, gasping, or irregular shallow respirations).
- Unresponsiveness, profound stupor, or inability to awaken the patient.
- New or worsening depression, sudden suicidal thoughts, or uncharacteristic aggressive outbursts.
- Severe allergic angioedema (swelling of the lips, tongue, or throat causing airway compromise).
09. Precautions and contraindications
| CATEGORY | CLINICAL CONTRAINDICATION & SAFETY RATIONALE |
|---|---|
| Absolute Contraindications | Patients who have experienced complex sleep behaviors after taking any Z-drug; severe respiratory failure; myasthenia gravis; severe hepatic impairment. |
| Sleep Apnea Syndrome | May compromise ventilatory compensation during hypoxic obstructive episodes; contraindicated in severe untreated sleep apnea. |
| Pre-existing Depression & Suicidality | Sedative-hypnotics can exacerbate clinical depression; closely monitor patients with mood disorders. |
| Pregnancy & Nursing | Crosses the placenta and passes into breast milk; may cause neonatal flaccidity and respiratory depression. Avoid unless potential benefits clearly justify fetal risk. |
10. Critical drug and substance interactions
Hepatic biotransformation via CYP3A4 makes these agents sensitive to enzyme inhibitors and inducers:
| INTERACTING SUBSTANCE | SEVERITY | MECHANISM & CLINICAL OUTCOME |
|---|---|---|
| Alcohol (Ethanol) | CONTRAINDICATED | Dramatically escalates incidence of complex sleep behaviors, amnesia, motor coordination failure, and fatal respiratory depression. |
| Opioids (Oxycodone, Hydrocodone, Tramadol, Morphine) | CONTRAINDICATED | Synergistic suppression of medullary respiratory drive; elevated risk of fatal nocturnal hypoventilation. |
| Potent CYP3A4 Inhibitors (Ketoconazole, Clarithromycin, Grapefruit) | MAJOR CAUTION | Blocks clearance, doubling plasma concentrations and causing prolonged next-day impairment. Eszopiclone starting dose must not exceed 1 mg. |
| Potent CYP3A4 Inducers (Rifampin, Carbamazepine, St. John’s Wort) | MAJOR CAUTION | Decreases eszopiclone exposure by over 80%, rendering the drug clinically ineffective. |
| Other Hypnotics & Sedatives (Zolpidem, Lorazepam, Carisoprodol) | AVOID | Redundant central nervous system depression, profound amnesia, and severe motor ataxia. |
11. Special populations & Beers criteria
Pediatric Use Guidelines
Safety and effectiveness of zopiclone and eszopiclone have not been established in pediatric patients under 18 years of age. A clinical trial in pediatric patients with ADHD-related insomnia failed to demonstrate efficacy and reported significant adverse psychiatric events.
12. Patient safety checklist
5-POINT SLEEP SAFETY CHECKLIST
-
✓
Full 7-to-8 Hour Sleep Window: Never take a dose unless you can remain in bed asleep for at least 7 to 8 full hours before waking. -
✓
Take Directly in Bed: Take the pill right as you get into bed. Do not take it while finishing work, reading, cooking, or walking around the house. -
✓
Absolute Zero Alcohol: Never combine sleeping pills with wine, beer, cocktails, or nighttime alcohol-containing liquid medicines. -
✓
Report Strange Nighttime Behaviors: Instruct family members to notify you immediately if they observe you sleepwalking, preparing food, or driving without memory of the event. -
✓
Short-Term Use Focus: Discuss non-pharmacological sleep techniques (CBT-I) with your clinician to avoid long-term psychological dependence.
13. Storage and safe disposal
As Schedule IV controlled substances, safe storage protocols must be adhered to at all times:
- Controlled Room Temperature: Store at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C and 30°C (59°F and 86°F). Protect from excessive moisture.
- Secure Storage: Keep in a locked medication safe or out-of-reach cabinet to prevent accidental ingestion by children or unauthorized access by visitors.
- Safe Disposal: Dispose of unwanted tablets through official DEA National Prescription Drug Take Back programs or pharmacy drop-boxes. If unavailable, mix with used coffee grounds or cat litter in a sealed bag before placing in household trash.
14. Frequently asked questions
Why does zopiclone cause a bitter metallic taste in the morning?
Zopiclone and its active metabolites are secreted directly into the salivary glands after systemic absorption. The taste is not from tablet residue in your throat, but from saliva carrying the drug molecules. Rinsing your mouth, using mints, or brushing teeth can help diminish the sensation.
How does eszopiclone compare to zolpidem (Ambien)?
Zolpidem has a shorter half-life (approximately 2.5 hours) and is primarily effective for falling asleep. Eszopiclone has a longer half-life (approximately 6 hours), making it significantly more effective for maintaining sleep throughout the entire night and preventing early morning awakenings.
Can I take zopiclone if I wake up at 3:00 AM?
No. You should never take zopiclone or eszopiclone in the middle of the night unless you have at least 7 to 8 full hours remaining before you must wake up and be functional. Taking it with fewer hours remaining causes severe morning sedation, memory impairment, and hazardous driving deficits.
15. References and verification sources
- U.S. Food and Drug Administration (FDA). Lunesta® (eszopiclone) Tablets Prescribing Information. Available from: FDA CDER Database.
- National Library of Medicine (DailyMed). Eszopiclone Tablet Package Insert and Clinical Pharmacology. Available from: NIH DailyMed Database.
- American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2023;71(7):2052-2081.
- StatPearls Publishing. Eszopiclone and Zopiclone: Mechanism, Side Effect Profile, and Complex Sleep Behaviors. Available from: NCBI Bookshelf StatPearls.
- VitalRxCare Sleep Guides. Insomnia, Sleep Apnea and Excessive Daytime Sleepiness Guide and Medication Safety Center Hub.
Have Questions About Your Sleep Prescription?
Our licensed clinical pharmacists are available to answer questions regarding dosing schedules, drug interactions, and safe tapering protocols.
Related Patient Services & Verified Care
Every prescription order is verified by a licensed pharmacist in strict adherence to FDA BeSafeRx protocols.